Skye Bioscience Receives Nasdaq Delisting Notice for Failing Minimum Bid Price Rule
SKYE is trading near its 52-week low of $0.61 (6.6% above the low) on light trading volume (0.2× avg).
Summary
Skye Bioscience, Inc. received a Nasdaq deficiency letter for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance and highlighting ongoing financial challenges.
Key Events · Corporate Governance and Compliance · SKYE
-
Nasdaq Deficiency Letter Received
Skye Bioscience, Inc. received a deficiency letter from Nasdaq on March 17, 2026, notifying the company of non-compliance with the minimum bid price rule.
-
Failure to Meet Minimum Bid Price
The company's common stock traded below the required $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1).
-
180-Day Compliance Period
Skye Bioscience has 180 calendar days, until September 14, 2026, to regain compliance. Options include achieving a $1.00 closing bid price for 10 consecutive days or executing a reverse stock split.
-
Follows Prior Delisting Risk Disclosure
This formal notice directly follows the company's 10-K filing on March 10, 2026, which explicitly warned of NASDAQ delisting risk due to its critical financial state and going concern warning.
Analysis · SKYE · Life Sciences
Skye Bioscience, Inc. received an official deficiency letter from Nasdaq due to its common stock trading below the $1.00 minimum bid price for 30 consecutive business days. This formal notice confirms a risk previously highlighted in the company's 10-K filing on March 10, 2026, which warned of a going concern and Nasdaq delisting risk. The company now has 180 calendar days, until September 14, 2026, to regain compliance. Failure to do so could lead to delisting, although a second 180-day period may be available under certain conditions. The company's options include achieving a $1.00 bid price for 10 consecutive days or implementing a reverse stock split. This event underscores the severe financial challenges the company faces, as previously indicated by its going concern warning and significant net losses.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 41.2% of the 452 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.9M. The 52-week trading range was $0.61 to $5.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.